Moderna's mRNA RSV vaccine delivers impressive Phase 3 trial results
Biotechnology company Moderna has announced promising results from its massive Phase 3 trial testing an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. The data indicates the vaccine is nearly 84% effective at preventing moderate disease and the company expects to file for US…| New Atlas
